Acknowledgement
We specially thank Dr. Seon Min Lee for interpretation of measurements of fecal calprotectin and Dr. Seong Jang Kim for statistical analysis.
References
- Peyrin-Biroulet L, Sandborn W, Sands BE, Reinisch W, Bemelman W, Bryant RV, et al. Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): determining therapeutic goals for treatto-target. Am J Gastroenterol 2015;110:1324-38. https://doi.org/10.1038/ajg.2015.233
- Zubin G, Peter L. Predicting endoscopic Crohn's disease activity before and after induction therapy in children: a comprehensive assessment of PCDAI, CRP, and fecal calprotectin. Inflamm Bowel Dis 2015;21:1386-91.
- Tibble JA, Sigthorsson G, Foster R, Forgacs I, Bjarnason I. Use of surrogate markers of inflammation and Rome criteria to distinguish organic from nonorganic intestinal disease. Gastroenterology 2002;123:450-60. https://doi.org/10.1053/gast.2002.34755
- Leach ST, Day AS, Messenger R, Walters TD, Navas-Lopez VM, Sladek M, et al. Fecal markers of inflammation and disease activity in pediatric Crohn disease: results from the ImageKids study. J Pediatr Gastroenterol Nutr 2020;70:580-5. https://doi.org/10.1097/MPG.0000000000002615
- Schoepfer AM, Beglinger C, Straumann A, Trummler M, Vavricka SR, Bruegger LE, et al. Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn's disease (SES-CD) than CRP, blood leukocytes, and the CDAI. Am J Gastroenterol 2010;105:162-9. https://doi.org/10.1038/ajg.2009.545
- Sipponen T, Karkkainen P, Savilahti E, Kolho KL, Nuutinen H, Turunen U, et al. Correlation of faecal calprotectin and lactoferrin with an endoscopic score for Crohn's disease and histological findings. Aliment Pharmacol Ther 2008;28:1221-9. https://doi.org/10.1111/j.1365-2036.2008.03835.x
- Mooiweer E, Severs M, Schipper ME, Fidder HH, Siersema PD, Laheij RJ, et al. Low fecal calprotectin predicts sustained clinical remission in inflammatory bowel disease patients: a plea for deep remission. J Crohn's Colitis 2015;9:50-5. https://doi.org/10.1093/ecco-jcc/jju003
- Wright EK, Kamm MA, De Cruz P, Hamilton AL, Ritchie KJ, Krejany EO, et al. Measurement of fecal calprotectin improves monitoring and detection of recurrence of Crohn's disease after surgery. Gastroenterology 2015;148:938-47.e1. https://doi.org/10.1053/j.gastro.2015.01.026
- Pavlidis P, Gulati S, Dubois P, Chung-Faye G, Sherwood R, Bjarnason I, et al. Early change in faecal calprotectin predicts primary non-response to anti-TNFα therapy in Crohn's disease. Scand J Gastroenterol 2016;51:1447-52. https://doi.org/10.1080/00365521.2016.1205128
- Guidi L, Marzo M, Andrisani G, Felice C, Pugliese D, Mocci G, et al. Faecal calprotectin assay after induction with anti-Tumour Necrosis Factor α agents in inflammatory bowel disease: prediction of clinical response and mucosal healing at one year. Dig Liver Dis 2014;46:974-9. https://doi.org/10.1016/j.dld.2014.07.013
- Noh SM, Oh EH, Park SH, Lee JB, Kim JY, Park JC, et al. Association of faecal calprotectin level and combined endoscopic and radiological healing in patients with Crohn's disease receiving anti-tumour necrosis factor therapy. J Crohn's Colitis 2020;14:1231-40. https://doi.org/10.1093/ecco-jcc/jjaa042
- Ferreiro-Iglesias R, Barreiro-de Acosta M, Lorenzo-Gonzalez A, Dominguez-Munoz JE. Accuracy of consecutive fecal calprotectin measurements to predict relapse in inflammatory bowel disease patients under maintenance with anti-TNF therapy: a prospective longitudinal cohort study. J Clin Gastroenterol 2018;52:229-34. https://doi.org/10.1097/MCG.0000000000000774
- Foster AJ, Smyth M, Lakhani A, Jung B, Brant RF, Jacobson K. Consecutive fecal calprotectin measurements for predicting relapse in pediatric Crohn's disease patients. World J Gastroenterol 2019;25:1266-77. https://doi.org/10.3748/wjg.v25.i10.1266
- Daperno M, D'Haens G, Van Assche G, Baert F, Bulois P, Maunoury V, et al. Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD. Gastrointest Endosc 2004;60:505-12. https://doi.org/10.1016/S0016-5107(04)01878-4
- Copova I, Hradsky O, Zarubova K, Gonsorcikova L, Potuznikova K, Lerchova T, et al. Fecal calprotectin is not a clinically useful marker for the prediction of the early nonresponse to exclusive enteral nutrition in pediatric patients with Crohn disease. Eur J Pediatr 2018;177:1685-93. Erratum in: Eur J Pediatr 2018;177:1695.
- Kostas A, Siakavellas SI, Kosmidis C, Takou A, Nikou J, Maropoulos G, et al. Fecal calprotectin measurement is a marker of short-term clinical outcome and presence of mucosal healing in patients with inflammatory bowel disease. World J Gastroenterol 2017;23:7387-96. https://doi.org/10.3748/wjg.v23.i41.7387
- Beltran B, Iborra M, Saez-Gonzalez E, Marques-Minana MR, Moret I, Cerrillo E, et al. Fecal calprotectin pretreatment and induction infliximab levels for prediction of primary nonresponse to infliximab therapy in Crohn's disease. Dig Dis 2019;37:108-15. https://doi.org/10.1159/000492626
- D'Arcangelo G, Oliva S, Dilillo A, Viola F, Civitelli F, Isoldi S, et al. Predictors of long-term clinical and endoscopic remission in children with Crohn disease treated with infliximab. J Pediatr Gastroenterol Nutr 2019;68:841-6. https://doi.org/10.1097/MPG.0000000000002262
- Lee YM, Choi S, Choe BH, Jang HJ, Kim S, Koh H, et al. Association between fecal calprotectin and mucosal healing in pediatric patients with Crohn's disease who have achieved sustained clinical remission with anti-tumor necrosis factor agents. Gut Liver 2022;16:62-70. https://doi.org/10.5009/gnl20300
- Sipponen T, Bjorkesten CG, Farkkila M, Nuutinen H, Savilahti E, Kolho KL. Faecal calprotectin and lactoferrin are reliable surrogate markers of endoscopic response during Crohn's disease treatment. Scand J Gastroenterol 2010;45:325-31. https://doi.org/10.3109/00365520903483650
- D'Haens G, Ferrante M, Vermeire S, Baert F, Noman M, Moortgat L, et al. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. Inflamm Bowel Dis 2012;18:2218-24. https://doi.org/10.1002/ibd.22917
- Gisbert JP, Bermejo F, Perez-Calle JL, Taxonera C, Vera I, McNicholl AG, et al. Fecal calprotectin and lactoferrin for the prediction of inflammatory bowel disease relapse. Inflamm Bowel Dis 2009;15:1190-8. https://doi.org/10.1002/ibd.20933
- Kallel L, Ayadi I, Matri S, Fekih M, Mahmoud NB, Feki M, et al. Fecal calprotectin is a predictive marker of relapse in Crohn's disease involving the colon: a prospective study. Eur J Gastroenterol Hepatol 2010;22:340-5. https://doi.org/10.1097/MEG.0b013e32832bab49
- Jusue V, Chaparro M, Gisbert JP. Accuracy of fecal calprotectin for the prediction of endoscopic activity in patients with inflammatory bowel disease. Dig Liver Dis 2018;50:353-9. https://doi.org/10.1016/j.dld.2017.12.022